You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯環藥業(600513.SH)連續9漲停提示風險 動態市盈率已明顯高於醫藥製造業平均市盈率
格隆匯 02-06 17:35

格隆匯2月6日丨聯環藥業(600513.SH)公佈,公司股票近期漲幅較大,敬請廣大投資者注意投資風險,理性決策,審慎投資。

經公司自查,並書面徵詢公司控股股東江蘇聯環藥業集團有限公司和實際控制人,截至公告披露日,確認不存在應披露而未披露的重大信息。

公司主要從事化學藥品的研發、生產及銷售,主要產品包括泌尿系統藥、抗組胺藥和心血管藥等三大系列,用於治療其他疾病的藥物佔比相對較小。公司生產的美愈偽麻膠囊可用於緩解普通感冒和流行性感冒症狀,2018年公司該產品銷售額為0元,2019年1-9月銷售收入僅為3.56萬元,佔比極小。公司生產的硫酸黏菌素原料藥、鹽酸多西環素片、鹽酸美他環素片、巴洛沙星片、羅紅黴素膠囊等抗生素類藥物主要用於治療細菌真菌感染,上述5個品種2018年銷售收入為1047.43萬元,僅佔公司2018年營業收入的1.03%,2019年1-9月銷售收入為1200.12萬元,僅佔公司2019年1-9月營業收入的1.35%。(以上產品的2019年銷售數據為未經審計數據。)上述產品銷售額佔比極小。綜上,公司相關產品銷售收入絕對金額及銷售額佔比極小。

公司動態市盈率已明顯高於醫藥製造業平均市盈率,敬請廣大投資者注意投資風險,理性決策,審慎投資。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account